Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 2095-2102

  Manna, Sunil K ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; OKADAIC ACID; PHORBOL ESTER; PROTEIN TYROSINE KINASE; REDUCING AGENT; TERIFLUNOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR;

ARTICLE; BONE MARROW CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GLIOMA CELL; HELA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; REPORTER GENE; T LYMPHOCYTE; TIME;

ANILINE COMPOUNDS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; CERAMIDES; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DITHIOTHREITOL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, MDR; GENES, REPORTER; HOST CELL FACTOR C1; HUMANS; HYDROGEN PEROXIDE; HYDROXYBUTYRATES; I-KAPPA B PROTEINS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LIPOPOLYSACCHARIDES; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OCTAMER TRANSCRIPTION FACTOR-1; OKADAIC ACID; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033557695     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Verma, I. M., J. K. Stevenson, E. M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 9:2723.
2. Siebenlist, U., G. Franzo, and K. Brown. 1994. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10:405.
3. Bartlett, R. R., and R. Schleyerbach. 1985. Immunopharmacological profile of a novel isoxazole derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis in rat. Int. J. Immunopharmacol. 7:7.
4. Siemasko, K. F., A. S. F. Chong, J. W. Williams, E. G. Bremer, and A. Finnegan. 1996. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635.
5. Chog, A. S.-F., K. Rezai, H. M. Gebel, A Finnegan, P. Foster, X.-L. Xu, and J. W. Williams. 1995. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 61:140.
6. Cherwinski, H. M., R. G. Cohn, P. Cheung, D. J. Webster, Y.-Z. Xu, J. P Caulfield, J. M. Young, G. Nakano, and J. T. Ransom. 1995. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275:1043.
7. Lin, Y., H. Sobis, M. Vandeputte, and M. Waer. 1995. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. Transplant. Proc. 27:305.
8. Xu, X.-L., J. M. Williams, E. G. Bremer, A. Finnegan, and A. S. F. Chong. 1995. Inhibition of tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270:12398.
9. Zhou, G., and M. T. Kuo. 1997. NF-κB mediated induction of mdrlb expression by insulin in rat hepatoma cells. J. Biol. Chem. 272:15174.
10. Schreiber, E., M. Matthias, M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with mini-extracts, prepared from a small number of cells. Nucleic Acids Res. 17:6419.
11. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248.
12. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711.
13. Collart, M. A., P. Baeuerle, and P. Vassalli. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol. Cell. Biol. 10:1498.
14. Hassanain, H. H., W. Dai, and S. L. Gupta. 1993. Enhanced gel mobility shift assay for DNA-binding factors. Anal. Biochem. 213:162.
15. Singh, H., J. H. LeBowitz, A. S. Baldwin, Jr., and P. A. Sharp. 1988. Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA. Cell 52:415.
16. Singh, S., and B. B. Aggarwal. 1995. Protein tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-κB. J. Biol. Chem. 270:10631.
17. Reddy, S. A. G., M. M. Chaturvedi, B. G. Darney, H. Chan, M. Higuchi, and B. B. Aggarwal. 1994. Reconstitution of NF-κB activation induced by tumor necrosis factor requires membrane-associated components: comparison with pathway activated by ceramide. J. Biol. Chem. 269:25369.
18. Sambrook, J., E. E. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
19. Xu, X., J. W. Williams, H. Gong, A. Finnegan, and A. S. F. Chong. 1996 Two activities of immunosuppressive metabolite of leflunomide. A771726. Biochem. Pharmacol. 52:527.
20. Chaturvedi, M. M., R. LaPushin, and B. B. Aggarwal. 1994. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular responses. J. Biol. Chem. 269:14575.
21. Gin, D. K., and B. B. Aggarwal 1998. Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of TNF and reactive oxygen intermediates. J. Biol. Chem. 273:14008.
22. Huang, T.-S., S. C. Lee, and J.-K. Lin. 1991. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 88:5292.
23. Finco, T. S., A. A. Beg, and A. S. Baldwin 1994. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA 91:11884.
24. Mahon, T. M., and L. A. O'Neill. 1995. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270:28557.
25. 2O, and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:2005.
26. Thanos, D., and T. Maniatis 1995. NF-κB: a lesson in family values. Cell 80:529.
27. Imbert, V., R. A. Rupec, A. Livolsi, H. L. Pahl, E. B. M. Traenckner, C. Mueller-Dieckmann, D. Farahifar, B. Rossi, P. Auberger, P. A. Baeuerle, et al. 1996. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α. Cell 86:787.
28. Lee, F. S., J. Hagler, Z. J. Chen, and T. Maniatis. 1997. Activation of the IκBα kinase complex by MEKKI, a kinase of the JNK pathway. Cell 88:213.
29. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NF-κB induction by TNF. CD95 and IL-1. Nature 385:540.
30. Maniatis, T. 1997. Catalysis by a multiprotein IκB kinase complex. Science 278: 818.
31. Stancovski, I., and D. Baltimore 1997. NF-κB activation: the IκB kinase revealed? Cell 90:299.
32. Elder, R. T., X. Xu, J. W. Williams, H. Gong, A. Finnegsa, and A. S. F. Chong. 1997: The immunosuppressive metabolite of leftunomide, A771726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159:22.
33. Matter, T., K. Kochhar, R. Barlett, E. G. Bremer, and A. Finnegan. 1993. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334:161.
34. Siemasko, K., A. S. F. Chong, H. M. Jack, H. Gong, J. W. Williams, and A. Finnegan 1998. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160:1581.
35. Davis, J. P., G.A. Cain, W. J. Pitts, R.L. Magolda, and R. A. Copeland. 1996. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270.
36. Greene, S., K. Watanabe, J. Braatz-Trulson, and L. Lou. 1995. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. 50:861.
37. Williamson, R. A., C. M. Yea, P. A. Robson, A. P. Curnock, S. Gadher, A. B. Hambleton, K. Woodward, J.-M. Bruneau, P. Hambleton, D. Moss, et al. 1995. Dihydroorotate dehydrogenase is a high affinity binding protein for A771726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270:22467.
38. Xu, X., L. Blinder, J. Shen, H. Gong, A. Finnegan, J. W. Williams, and A. S. F. Chong. 1997. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr. mice. J. Immunol. 159:167.
39. Schutze, S., K. Pothoff, T. Machleidt, D. Bercovic, K. Wiegmann, and M. Kronke. 1992. TNF activates NF-κB by phosphatidylcholine specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 71:765.
40. Dressler, K. A., S. Mathias, and R. N. Kolesnick. 1992. Tumor necrosis factor-α activates the sphingomyelin signal transduction pathway in a cell-free system. Science. 255:1715.
41. Mathias, S., K. A. Dressler, and R. N. Kolesnick. 1991. Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor α. Proc. Natl. Acad. Sci. USA 88:10009.
42. Schulze-Osthoff, K., R. Beyaert, V. Van Dervoorde, G. Haegeman, and W. Fiers. 1993. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J. 12:3095.
43. Xiao, F., A. S. F. Chong, J. Shen, J. Yang, J. Short, P. Foster, H. Sankary, S. Jensik, D. Mital, L. McChesney, et al. 1995. Pharmacologically induced regression of chronic transplant rejection. Transplantation 60:1065.
44. Xiao, F., A. S. F. Chong, P. Foster, H. Sankary, J. L. McChesney, G. Koukoulis, J. Yang, D. Frieders, and J. W. Williams. 1994. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58:828.
45. Chong, A. S.-F., J. Shen, F. Xiao, L. Blinder, L. Wei, H. Sankary, P. Foster, and J. Williams. 1996. Delayed xenograft rejection in the concordant hamster heart to Lewis rat model. Transplantation 2:90.
46. Lucien, J., V. C. Dias, D. F. LeGatt, and R. W. Yatscoff. 1995. Blood distribution and single-dose pharmakinetics of leflunomide. Ther. Drug Monitor 17:454.